Clinical Trial Update: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer [Phase 1]

View source ↗

Summary

Clinical Trial Update noting the completion of the Phase 1 portion of RGX-202-01 (Ompenaclid) in combination therapy for RAS-mutant advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Ompenaclid (Ompenaclid)

Snippet

Sponsor: Inspirna, Inc. | Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 1 | Status: COMPLETED